Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Vedere Bio II

Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2020
Status: Out of Business

BioCentury | Jul 26, 2023
Management Tracks

New CEOs for Catalyst, FibroGen, Pheon and Tae

Plus: Nicole Sweeny named chief commercial officer of KalVista 
BioCentury | Apr 4, 2023
Regulation

April 3 Quick Takes: Padcev label expanded to first-line urothelial cancer

Plus: Ascendis’ market cap melts as thyroid program hits FDA snag and updates from Apellis, Vedere and Vertex-CRISPR 
BioCentury | May 20, 2022
Discovery & Translation

Optimizing CNS tropism for AAVs at ASGCT

Directed evolution, genetic library screening and peptide modifications were the most common strategies presented
BioCentury | Apr 26, 2022
Management Tracks

Stoffels becomes Galapagos board chairman

Plus Vedere Bio II and management moves at Jnana, Flare, DeepCure and more
BioCentury | Apr 12, 2022
Management Tracks

Consylman now at Vedere Bio II

Plus Neuron23 hires Jackson and updates from Sitryx, Illumina, Alto and more
BioCentury | Jun 22, 2021
Management Tracks

Wigerinck to leave Galapagos; plus Kymera, Alladapt, Nurix, Alchemab, Novome and more

Piet Wigerinck will step down this year after serving as CSO for nine years at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), overseeing the Belgian biotech’s programs from the discovery of
BioCentury | May 18, 2021
Finance

May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more

Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
BioCentury | Oct 30, 2020
Deals

Via takeout of Atlas-grown optogenetic play for $150M up front, Novartis adds to gene therapy arsenal 

Vedere Bio II spins out with vision restoration and preservation programs
Items per page:
1 - 8 of 8
Help Center
Username
Request a Demo
Request Training
Ask a Question